TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 · November 3, 2025 · 3 pages
Preview the first 2 pages of this press release
Create a free account to start reading
Full documents are included with Professional
Earnings release
6 pages
Nov 12, 2025
Quarterly report
94 pages
Nov 12, 2025
Presentation
TScan Therapeutics Corporate Deck_November 2025_vF
30 pages
Presentation
ASH 2025 KOL call_vFINAL
30 pages
Presentation
TScan Update Call November 2025
4 pages
Presentation
TScan Therapeutics Corporate Deck_December 2025_vF
30 pages
Press release
TScan Therapeutics Announces Positive Updated Data from the ALLOHA⢠Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
3 pages
Dec 8, 2025
Press release
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
3 pages
Nov 3, 2025